Literature DB >> 11733265

Circumscribed choroidal hemangioma: clinical manifestations and factors predictive of visual outcome in 200 consecutive cases.

C L Shields1, S G Honavar, J A Shields, J Cater, H Demirci.   

Abstract

PURPOSE: To review the clinical features and management of circumscribed choroidal hemangioma and determine factors predictive of poor visual outcome.
DESIGN: Retrospective consecutive noncomparative interventional case series. PARTICIPANTS: Two hundred consecutive patients with circumscribed choroidal hemangioma. MAIN OUTCOME MEASURES: The main outcome measures were analyzed in 155 patients with follow-up of at least 3 months and included complete resolution of subretinal fluid, worsening of visual acuity (more than 2 Snellen lines), and poor final visual acuity (20/200 or worse).
RESULTS: The patients were seen at a mean age of 45 years with symptoms of decreased visual acuity (81%), visual field defect (7%), metamorphopsia (3%), floaters (2%), progressive hypermetropia (1%), photopsia (1%), pain (1%), and no symptoms (6%). The referring diagnoses were choroidal hemangioma (29%), choroidal melanoma (29%), choroidal metastasis (9%), retinal detachment (6%), central serous chorioretinopathy (5%), and others. The tumor had a median base of 6.0 mm and median thickness of 3.0 mm. Secondary retinal detachment in the foveal region was present in 81% of the patients. Initial treatment included observation (51%), laser photocoagulation (44%), plaque radiotherapy (4%), external beam radiotherapy (1%), surgical repair of retinal detachment (1%), and enucleation for painful neovascular glaucoma (1%). Kaplan-Meier estimates revealed complete resolution of subretinal fluid in 60% patients at 5 years and 76% patients at 10 years follow-up. By multivariable analysis, clinical factors predictive of complete resolution of subretinal fluid included shorter duration of symptoms (P = 0.03) and inferior quadrant location of tumor (P = 0.001). At initial presentation, 82 of 155 (53%) patients had poor visual acuity (20/200 or worse), and 73 of 155 (47%) patients had good to moderate visual acuity (20/100 or better). Of those 82 patients with poor initial vision, poor final vision was found in 54% at 5 years and 80% at 10 years. Of the 73 patients with good to moderate initial vision, poor final vision was found in 12% at 5 years and 43% at 10 years. By multivariable analysis, clinical factors predictive of poor final visual acuity included poor initial visual acuity (P < 0.001), failure of previous laser photocoagulation before referral (P = 0.01), and tumor management with observation after referral (P = 0.02). Worsening of visual acuity (by more than 2 Snellen lines) was observed in 8% at 5 years and 28% at 10 years of those 82 patients who were initially seen with poor vision. Worsening of visual acuity was found in 10% at 5 years and 30% at 10 years of those 73 patients who initially were seen with good to moderate vision.
CONCLUSIONS: Circumscribed choroidal hemangioma is a rare intraocular tumor. In 38% of cases, this tumor is initially misinterpreted before referral as choroidal melanoma or metastasis. Visual acuity is poor in more than 60% of patients at 10 years, despite successful control of associated subretinal fluid in 76% patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11733265     DOI: 10.1016/s0161-6420(01)00812-0

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  52 in total

1.  Transpupillary thermotherapy in the treatment of circumscribed choroidal hemangiomas.

Authors:  Raul N G Vianna; Luiza Fernandes; Acácio Muralha; Aderbal Alves Júnior; Lilia Muralha; Eduardo Muranaka
Journal:  Int Ophthalmol       Date:  2004-03       Impact factor: 2.031

Review 2.  Lasers for the treatment of intraocular tumors.

Authors:  Samuel K Houston; Charles C Wykoff; Audina M Berrocal; Ditte J Hess; Timothy G Murray
Journal:  Lasers Med Sci       Date:  2013-05       Impact factor: 3.161

3.  Mobile lens-induced angle closure glaucoma and rubeosis iridis in Sturge Weber syndrome.

Authors:  Dong Hyun Lee; Jonghoon Shin; Jae Hyun Seo; Ik Soo Byon; Jae Ho Jung; Ji Eun Lee
Journal:  Int J Ophthalmol       Date:  2015-10-18       Impact factor: 1.779

Review 4.  The role of photodynamic therapy in the treatment of symptomatic choroidal hemangioma.

Authors:  Bernhard Jurklies; Norbert Bornfeld
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-02-08       Impact factor: 3.117

Review 5.  Neovascular glaucoma.

Authors:  Sohan Singh Hayreh
Journal:  Prog Retin Eye Res       Date:  2007-08-08       Impact factor: 21.198

6.  Regression of choroidal hemangioma following systemic paclitaxel and trastuzumab use.

Authors:  Hayyam Kiratli; Salih Uzun; Berçin Tarlan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-12-03       Impact factor: 3.117

7.  Application of intravitreal bevacizumab for circumscribed choroidal hemangioma.

Authors:  Min Sagong; Junyeop Lee; Woohyok Chang
Journal:  Korean J Ophthalmol       Date:  2009-06-09

8.  Photodynamic therapy using verteporfin in circumscribed choroidal haemangioma.

Authors:  B Jurklies; G Anastassiou; S Ortmans; A Schüler; H Schilling; U Schmidt-Erfurth; N Bornfeld
Journal:  Br J Ophthalmol       Date:  2003-01       Impact factor: 4.638

9.  Long-term (4 years) results of choroidal hemangioma treated with proton beam irradiation.

Authors:  A Zeisberg; I Seibel; D Cordini; N Lakotka; G Willerding; L Moser; J Heufelder; A M Joussen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-04-29       Impact factor: 3.117

Review 10.  Photodynamic therapy of circumscribed choroidal haemangioma.

Authors:  A D Singh; P K Kaiser; J E Sears; M Gupta; P A Rundle; I G Rennie
Journal:  Br J Ophthalmol       Date:  2004-11       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.